Perceived effectiveness of antiretroviral therapy,self-rated health and treatment adherence among HIV-positive people who inject drugs in Estonia

Abstract

The HIV epidemic in Estonia affects the population of people who inject drugs (PWID) the most, but factors associated with adherence to antiretroviral therapy (ART) among PWID have not been thoroughly examined in Estonia, with particularly limited data regarding beliefs and attitudes of PWID. The objective of this study was to explore the association between ART adherence and individual beliefs, perceived effectiveness of ART, and self-rated health in particular, in this specific population. The study used baseline survey data from a longitudinal intervention study of HIV prevention among PWID in Estonia, in which 107 HIV-infected participants reported current use of ART. Current adherence was measured through the use of a visual analog scale. Approximately half (49%) of the participants reported optimal (≥95%) adherence. The vast majority (81%) believed in the effectiveness of ART. Less than a quarter of the participants (22%) rated their health as good or very good, and a half (52%) reported average health. Individual beliefs and self-reported health were not associated with ART adherence in both bivariate and multivariable analyses. Participants with problem drinking reported significant suboptimal adherence to ART (adjusted odds ratio [AOR] 0.42, 95% CI 0.19–0.97). Daily injection drug use was also associated with suboptimal adherence (AOR 0.34, 95% CI 0.13–0.91). Problem drinking has not been commonly reported as a factor of suboptimal ART adherence among PWID; further research would be useful to identify the pathways that might be involved.

Keywords

HIV AIDS treatment Europe ART

Get full access to this article

View all access options for this article.

References

European Centre for Disease Prevention and Control/World Health Organization. HIV/AIDS surveillance in Europe 2012, http://www.euro.who.int/__data/assets/pdf_file/0018/235440/e96953.pdf (2013, accessed 1 July 2015).

World Health Organization. HIV/AIDS, http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/hivaids (2015, accessed 1 July 2015).

Joint United Nations Programme on HIV/AIDS. AIDS by the numbers, http://www.unaids.org/sites/default/files/media_asset/JC2571_AIDS_by_the_numbers_en_1.pdf (2013, accessed 1 July 2015).

World Health Organization. Figures talk: HIV/AIDS in the WHO European Region, 2012. Halting and reversing the spread of HIV by 2015 are at stake, http://www.euro.who.int/__data/assets/pdf_file/0006/235599/WAD-Fact-sheet-Eng.pdf (2013, accessed 1 July 2015).

European Centre for Disease Prevention and Control / World Health Organization. HIV/AIDS surveillance in Europe 2013, http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-Europe-2013.pdf (2014, accessed 1 July 2015).

Joint United Nations Programme on HIV/AIDS. The gap report, http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf (2014, accessed 1 July 2015).

Laisaar

Avi

DeHovitz

et al.

Estonia at the threshold of the fourth decade of the AIDS era in Europe. AIDS Res Hum Retroviruses 2011; 27: 841–851.

World Health Organization. Key Facts on HIV Epidemic in Estonia and Progress in 2011, http://www.euro.who.int/__data/assets/pdf_file/0004/188752/Estonia-HIVAIDS-Country-Profile-2011-revision-2012-final.pdf (2013, accessed 1 July 2015).

Abel-Ollo

Rahu

Rajaleid

et al.

Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care 2009; 21: 851–857.

10.

Platt

Bobrova

Rhodes

et al.

High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS 2006; 20: 2120–2123.

11.

Uusküla

Des Jarlais

Kals

et al.

Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health 2011; 11: 517–517.

12.

Vorobjov

Uusküla

Des Jarlais

et al.

Multiple routes of drug administration and HIV risk among injecting drug users. J Subst Abuse Treat 2012; 42: 413–420.

13.

Arnsten

Mizuno

et al.

Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr 2007; 46: S64–71.

14.

Degroote

Vogelaers

Vermeir

et al.

Determinants of adherence in a cohort of Belgian HIV patients: a pilot study. Acta Clin Belg 2014; 69: 111–115.

15.

Cohen

Chen

McCauley

et al.

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493–505.

16.

Donnell

Baeten

Kiarie

et al.

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092–2098.

17.

Uusküla

Des Jarlais

Raag

et al.

Combined prevention for persons who inject drugs in the HIV epidemic in a transitional country: the case of Tallinn, Estonia. AIDS Care 2015; 27: 105–111.

18.

von Wyl V, Klimkait T, Yerly S, et al. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV cohort study. PLoS One 8: e77691.

19.

Maggiolo

Ravasio

Ripamonti

et al.

Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158–163.

20.

Vlahov

Celentano

. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saude Publica 2006; 22: 705–718.

21.

Malta

Magnanini

Strathdee

et al.

Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14: 731–747.

22.

Kamarulzaman

Altice

. Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis 2015; 28: 10–16.

23.

Nolan

Milloy

Zhang

et al.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care 2011; 23: 980–987.

24.

Altice

Mostashari

Friedland

. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28: 47–58.

25.

Carrieri

Chesney

Spire

et al.

Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003; 10: 1–14.

26.

Clarke

Delamere

McCullough

et al.

Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med 2003; 4: 33–37.

27.

Mimiaga

Safren

Dvoryak

et al.

“We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care 2010; 22: 1305–1313.

28.

Wolfe

. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy 2007; 18: 246–254.

29.

Fumaz

Munoz-Moreno

Molto

et al.

Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care 2008; 20: 796–805.

30.

Horne

Buick

Fisher

et al.

Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004; 15: 38–44.

31.

Johnson

Catz

Remien

et al.

Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS 2003; 17: 645–656.

32.

Uusküla

Laisaar

Raag

et al.

Antiretroviral therapy (ART) adherence and correlates to nonadherence among people on ART in Estonia. AIDS Care 2012; 24: 1470–1479.

33.

Waldrop-Valverde

Dong

Ownby

. Medication-taking self-efficacy and medication adherence among HIV-infected cocaine users. J Assoc Nurses AIDS Care 2013; 24: 198–206.

34.

Zúñiga

Muñoz

Kozo

et al.

A binational study of patient-initiated changes to antiretroviral therapy regimen among HIV-positive Latinos living in the Mexico–U.S. border region. AIDS Behav 2012; 16: 1622–1629.

35.

Boileau

Nguyen

-K Sylla

et al.

Low prevalence of detectable HIV plasma viremia in patients treated with ART in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48: 476–484.

36.

Uusküla

Laisaar

K-T

Raag

et al.

ART adherence and correlates to nonadherence among people on ART in Estonia. AIDS Care 2012; 24: 1470–1479.

37.

Heckathorn

. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 1997; 49: 11–34.

38.

Des Jarlais

Perlis

Stimson

et al.

Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II. BMC Public Health 2006; 6: 54–54.

39.

Chkhartishvili

Rukhadze

Svanidze

et al.

Evaluation of multiple measures of antiretroviral adherence in the Eastern European country of Georgia. J Int AIDS Soc 2014; 17: 18885–18885.

40.

Meyer JC, Summers B, Lentsoane PP, et al. Is a simple self-rating or visual analogue scale (VAS) more reliable than prescription refill (PR) data as an indicator of non-adherence in a resource-limited setting in South Africa? 7th International Conference on HIV Treatment and Prevention Adherence, Miami, USA, 3–5 June 2012. Available at: http://www.iapac.org/AdherenceConference/assets/Adherence2012_Program.pdf (accessed 6 June 2017).

41.

Giordano

Guzman

Clark

et al.

Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004; 5: 74–79.

42.

Kalichman

Amaral

Swetzes

et al.

A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care 2009; 8: 367–374.

43.

Walsh

Mandalia

Gazzard

. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269–277.

44.

Ewing

. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252: 1905–1907.

45.

Berwick

Murphy

Goldman

et al.

Performance of a five-item mental health screening test. Med Care 1991; 29: 169–176.

46.

Holmes

. A short, psychiatric, case-finding measure for HIV seropositive outpatients: performance characteristics of the 5-item mental health subscale of the SF-20 in a male, seropositive sample. Med Care 1998; 36: 237–243.

47.

Vittinghoff

Glidden

Shiboski

et al.

Regression methods in biostatistics: linear, logistic, survival, and repeated measures models, New York: Springer, 2015.

48.

Feelemyer

Des Jarlais

Arasteh

et al.

Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review. AIDS Behav 2015; 19: 575–583.

49.

Mann

Milloy

Kerr

et al.

Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users. HIV Med 2012; 13: 596–601.

50.

Turner

. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002; 185: S143–151.

51.

Langebeek

Gisolf

Reiss

et al.

Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med 2014; 12: 142–142.

52.

Uusküla

Raag

Vorobjov

et al.

Non-fatal overdoses and related risk factors among people who inject drugs in St. Petersburg, Russia and Kohtla-Järve, Estonia. BMC Public Health 2015; 15: 1255–1255.

53.

Henrich

Lauder

Desai

et al.

Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Community Health 2008; 33: 69–77.

54.

Chander

Lau

Moore

. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006; 43: 411–417.

55.

Kahler CW, Liu T, Cioe PA, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav. Epub ahead of print 8 July 2016. DOI: 10.1007/s10461-016-1474-y.

56.

Palepu

Tyndall

et al.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003; 80: 667–675.

57.

Tran

Nguyen

et al.

Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health 2014; 14: 27–27.

58.

Weber

Huber

Rickenbach

et al.

Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009; 10: 407–416.

59.

Westergaard

Hess

Astemborski

et al.

Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS 2013; 27: 2559–2566.

60.

Becker

. The health belief model and personal health behavior. Health Educ Monogr 1974; 2: 354–386.